- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Samsca, Jynarque
Synonyms :
tolvaptan
Class :
Vasopressin Antagonists; Vasopressin-Related
Dosage Forms & Strengths
tablet (Samsca)
30mg
15mg
tablet (Jynarque)
90mg
60mg
45mg
30mg
15mg
Safety and efficacy not established
Refer to the adult dosing regimen
may enhance the serum concentration when combined with tolvaptan
may enhance the serum concentration when combined with tolvaptan
may enhance the serum concentration when combined with tolvaptan
may enhance the serum concentration when combined with tolvaptan
may enhance the serum concentration when combined with tolvaptan
tolvaptan: they may enhance the serum concentration of CYP3A Inhibitors
tolvaptan: they may enhance the serum concentration of CYP3A Inhibitors
tolvaptan: they may enhance the serum concentration of CYP3A Inhibitors
tolvaptan: they may enhance the serum concentration of CYP3A Inhibitors
tolvaptan: they may enhance the serum concentration of CYP3A Inhibitors
may diminish the serum concentration when combined with tolvaptan
may diminish the serum concentration when combined with tolvaptan
may diminish the serum concentration when combined with tolvaptan
may diminish the serum concentration when combined with tolvaptan
may diminish the serum concentration when combined with tolvaptan
may decrease the therapeutic effect when combined with desmopressin
may increase the adverse effect when combined with tolvaptan
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of tolvaptan
may enhance the serum concentration of CYP3A4 inhibitors
sodium chloride increases the toxicity of tolvaptan
may increase the hyperkalemic effect when combined with angiotensin II receptor blockers
may increase the hyperkalemic effect when combined with angiotensin II receptor blockers
may increase the hyperkalemic effect when combined with angiotensin II receptor blockers
may increase the hyperkalemic effect when combined with angiotensin II receptor blockers
may increase the hyperkalemic effect when combined with angiotensin II receptor blockers
may increase the hyperkalemic effect when combined with ace inhibitors
may increase the hyperkalemic effect when combined with ace inhibitors
may increase the hyperkalemic effect when combined with ace inhibitors
may increase the hyperkalemic effect when combined with ace inhibitors
may increase the hyperkalemic effect when combined with ace inhibitors
may diminish the serum concentration when combined with tolvaptan
may diminish the serum concentration when combined with tolvaptan
may enhance the serum concentration when combined with digoxin
spironolactone and hydrochlorothiazide
may increase the hyperkalemic effect when combined with potassium-sparing diuretics
may increase the hyperkalemic effect when combined with potassium-sparing diuretics
may increase the hyperkalemic effect when combined with potassium-sparing diuretics
may increase the hyperkalemic effect when combined with potassium-sparing diuretics
may increase the hyperkalemic effect when combined with potassium-sparing diuretics
It may enhance the metabolism when combined with dexamethasone
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
spironolactone and hydrochlorothiazide
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
when both drugs are combined, there may be a high metabolism of tolvaptan
the effect of tolvaptan is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
it enhances the serum potassium levels
it may enhance the serum potassium levels
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
Actions and spectrum:
The actions of tolvaptan include:
The spectrum of tolvaptan includes:
Frequency defined
>10%
Samsca
Jynarque
1-10%
Samsca
Jynarque
Post marketing Reports
Investigations: Hypernatremia
Hepatobiliary disorders: Liver failure